市場調查報告書
商品編碼
1466666
RNA干擾技術市場:按類型、治療方法、應用分類 - 2024-2030 年全球預測RNA Interference Technology Market by Type (dsRNA, miRNA, siRNA), Therapeutics (Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders), Application - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年RNA干擾技術市場規模為329.2億美元,預計2024年將達392.5億美元,2030年將達1,354億美元,複合年成長率為22.38%。
RNA干擾(RNAi) 技術市場包括使用小 RNA 控制基因表現的系統。該技術可應用於功能基因組學、治療開發和農業害蟲防治。該市場包括各種相關產品,如試劑、siRNA、shRNA、 微型RNA以及基於 RNAi 的研發服務。影響RNAi技術市場成長的主要因素包括基因治療的進步和遺傳疾病盛行率的增加。此外,增加對藥物發現和開發過程的投資也支持 RNAi。儘管RNAi技術市場具有巨大的成長潛力,但也存在顯著的限制和挑戰,例如難以有效地將RNAi分子遞送至目標細胞並確保其在體內的穩定性。存在意外基因靜默的風險,導致脫靶效應和潛在毒性。然而,基因治療的進步和遺傳疾病盛行率的增加。增加對使用 RNAi 的藥物發現和開發過程的投資。
主要市場統計 | |
---|---|
基準年[2023] | 329.2億美元 |
預測年份 [2024] | 392.5億美元 |
預測年份 [2030] | 1,354億美元 |
複合年成長率(%) | 22.38% |
類型:利用siRNA進行標靶基因治療治療多種疾病
dsRNA 作為 RNAi途徑的前驅分子,被細胞機器辨識並加工成較小的 RNAi 有效分子。 miRNA 是一種在植物、動物和一些病毒中發現的小非編碼 RNA 分子,其功能是 RNA定序和基因表現的轉錄後調控。 siRNA是一種雙鏈RNA分子,長度通常為20至25個鹼基對,可抑制具有互補鹼基序列的特定基因的表達。 siRNA 在 mRNA 層面上針對遺傳異常並抑制其表達,使其成為藥物開發的優先領域,尤其是在基因治療領域。 dsRNA 的穩定性和廣泛的活性有利於農業用途和病毒防禦研究的早期階段,而 miRNA 在基因調控中的作用則為複雜疾病的治療和診斷帶來了希望。
RNA干擾技術在應用藥物發現與開發上的快速普及
藥物發現和開發中的 RNAi 主要用於識別基因功能和檢驗藥物標靶。 RNAi 使研究人員能夠以可逆且高度特異性的方式有效沉默基因,從而更容易識別特定基因如何參與疾病。 RNAi技術可直接應用於治療醫學領域,以沉默致病基因。這導致了新藥的開發,特別是針對單基因突變引起的疾病,以及傳統小分子藥物和生技藥品無效的疾病。 RNAi 的治療應用適用於已知遺傳基礎的疾病,例如某些癌症、病毒感染和遺傳性疾病。
區域洞察
在美洲, RNA干擾(RNAi)技術取得了重大進展,特別是在生物技術和製藥領域。美國是這一領域的領導者,擁有大量促進創新的公司和研究機構。美國國立衛生美國(NIH) 的努力以及致力於 RNAi 的生物技術中心內的合作正在推動進一步的研究和開發。此外,創業投資擴大投資於利用 RNAi 進行基因靜默的新興企業,這些公司適用於從癌症治療到遺傳疾病等各種醫療應用。 EMEA(歐洲、中東和非洲)地區呈現出 RNAi 技術的多元化格局,其中歐洲在臨床開發和研究方面主導。德國 Silence Therapeutics 和 CureVac 等歐洲生物技術公司為基於 RNAi 的療法的開發做出了貢獻。此外,歐洲藥品管理局 (EMA) 為 RNAi 藥物的核准提供了強力的框架,進一步促進了該領域的發展。由歐盟 (EU) 各種框架計劃資助的生物醫學研究界繼續為 RNAi 的理解和應用做出貢獻。中東和非洲市場的活動日益活躍,學術機構渴望探索 RNAi 的潛力,以縮小技術差距並解決地方性疾病。亞太地區的 RNAi 技術呈現快速成長,重點是創新和市場擴張。日本和中國處於這一成長的最前沿,在生物技術研究和快速發展的製藥業進行投資。政府的舉措以及與國際生物技術公司的合作對該行業的發展做出了重大貢獻,學術研究機構正在提供有關 RNAi 機制的基本見解。此外,該地區擴大參與全球臨床臨床實驗,這表明該地區致力於將 RNAi 療法整合到醫療保健系統中。這種整合是由亞太地區動態的監管環境所推動的,並努力應對不斷變化的科學環境。
FPNV定位矩陣
FPNV定位矩陣對於評估RNA干擾技術市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對RNA干擾技術市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. RNA干擾技術市場規模及預測是多少?
2. RNA干擾技術市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些?
3. RNA干擾技術市場的技術趨勢與法規結構是什麼?
4. RNA干擾技術市場主要廠商的市場佔有率為何?
5. 進入RNA干擾技術市場的適當型態和策略手段是什麼?
[195 Pages Report] The RNA Interference Technology Market size was estimated at USD 32.92 billion in 2023 and expected to reach USD 39.25 billion in 2024, at a CAGR 22.38% to reach USD 135.40 billion by 2030.
The RNA interference (RNAi) technology market encompasses systems that use small RNA molecules to regulate gene expression. This technology is applicable in functional genomics, therapeutic developments, and agriculture for pest control. It encompasses various related products such as reagents, siRNA, shRNA, and microRNA and services for RNAi-based research and development. The key factors influencing the growth of the RNAi technology market include advancements in gene therapy and the increasing prevalence of genetic disorders. Additionally, rising investments in drug discovery and development processes are driven by RNAi. While the RNAi technology market presents significant growth potential, there are notable limitations and challenges, including difficulty in delivering RNAi molecules effectively to targeted cells and ensuring their stability within the body. Risk of unintended gene silencing, leading to off-target effects and potential toxicity. However, advancements in gene therapy and the increasing prevalence of genetic disorders. Rising investments in drug discovery and development processes driven by RNAi.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 32.92 billion |
Estimated Year [2024] | USD 39.25 billion |
Forecast Year [2030] | USD 135.40 billion |
CAGR (%) | 22.38% |
Type: siRNA's use for targeted gene therapy for treating a multitude of diseases
dsRNA acts as the precursor molecule in the RNAi pathway and is recognized by the cell's machinery to be processed into smaller RNAi-effective molecules. It triggers a natural defense mechanism against RNA viruses and is used in various applications, including agricultural biotechnology and therapeutic developments. miRNA is a small non-coding RNA molecule found in plants, animals, and some viruses, which functions in RNA silencing and post-transcriptional regulation of gene expression. Research into miRNA has surged due to its role in regulating cellular functions and implications in various diseases, including cancer. siRNA is a class of double-stranded RNA molecules, typically 20-25 base pairs in length that interfere with the expression of specific genes with complementary nucleotide sequences. siRNA has been a focus area for drug development, notably in gene therapy, to target and silence genetic abnormalities at the mRNA level. dsRNA's stable nature and broad-spectrum activity make it favorable for agricultural use and the initial stages of viral defense research, while miRNA's role in gene regulation offers promise for complex disease therapy and diagnostics. siRNA's high specificity and reduced off-target effects position it as a frontrunner in targeted gene therapy for many diseases.
Application: Exponential adoption of RNA interference technology for dru discovery & development
The RNAi in drug discovery and development is primarily used to identify the function of genes and validate drug targets. RNAi allows researchers to efficiently silence genes in a reversible and highly specific manner, which facilitates identifying how particular genes contribute to disease. RNAi technology is applied directly to silence disease-causing genes in the therapeutics segment. This has led to the development of new medicines, particularly for diseases caused by single-gene mutations or where traditional small-molecule drugs or biologics have been ineffective. Therapeutic application of RNAi is preferred for diseases with known genetic bases, such as certain types of cancer, viral infections, and inherited genetic disorders.
Regional Insights
In the Americas, RNA interference (RNAi) technology has seen significant advancement, particularly within the biotechnology and pharmaceutical sectors. The United States leads in this space, with a strong presence of companies and research institutions driving innovation. Initiatives by the National Institutes of Health (NIH) and collaborations within RNAi-focused biotech hubs promote further research and development. Additionally, venture capital is increasingly funding startups that leverage RNAi for gene silencing in various medical applications, ranging from cancer therapy to genetic disorders. The EMEA region shows a diverse landscape for RNAi technology, with Europe taking the lead in clinical development and research. European biotech companies, such as Silence Therapeutics and CureVac in Germany, have been instrumental in advancing RNAi-based therapeutics. Moreover, the European Medicines Agency (EMA) provides a robust framework for RNAi drug approval, further facilitating growth in this domain. The biomedical research community, supported by funding from the European Union through various Framework Programmes, continues to contribute to the understanding and application of RNAi. Activity within the Middle East and African markets is emerging, with research primarily driven by academic institutions eager to bridge the technology gap and explore RNAi's potential in tackling region-specific diseases. The Asia-Pacific region demonstrates rapid growth in RNAi technology with a strong emphasis on innovation and market expansion. Japan and China are at the forefront of this growth due to their investments in biotechnology research and quickly evolving pharmaceutical sectors. Government initiatives and collaborations with international biotech firms have significantly contributed to the industry's growth, with academic research institutions providing foundational insights into RNAi mechanisms. Additionally, the region's increasing participation in global clinical trials exhibits a commitment to integrating RNAi therapeutics into their healthcare systems. This integration is facilitated by APAC's dynamic regulatory environment, striving to keep pace with the evolving scientific landscape.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the RNA Interference Technology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Interference Technology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the RNA Interference Technology Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., AMSBIO, Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Atalanta Therapeutics, Bioneer Corporation, CureVac N.V., Dicerna Pharmaceuticals, Inc., Gotham Therapeutics Corp., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Merck KGaA, NeuBase Therapeutics, Inc., Novartis AG, Nutcracker Therapeutics, Inc., Phio Pharmaceuticals Corp., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the RNA Interference Technology Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Interference Technology Market?
3. What are the technology trends and regulatory frameworks in the RNA Interference Technology Market?
4. What is the market share of the leading vendors in the RNA Interference Technology Market?
5. Which modes and strategic moves are suitable for entering the RNA Interference Technology Market?